Oppenheimer Upgrades GW Pharma (GWPH) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St climbs after Fed's Waller says he could support rate hold
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
GW Pharma (GWPH) PT Raised to $227 at Stifel
May 7, 2019 8:37 AM EDTStifel analyst Paul Matteis raised the price target on GW Pharma (NASDAQ: GWPH) to $227.00 (from $191.00) while maintaining a Buy rating after spending time with management post 1Q print. The company reaffirmed views that the Epidiolex launch to date, considering all of the... More
GW Pharma (GWPH) PT Raised to $200 at Cowen
May 7, 2019 6:43 AM EDTCowen analyst Phil Nadeau raised the price target on GW Pharma (NASDAQ: GWPH) to $200.00 (from $175.00) while maintaining a Outperform rating following results.
The analyst commented, "GW reported $33.5MM in Epidiolex revenue during its first full quarter on the market, well ahead of consensus... More
GW Pharma (GWPH) PT Raised to $229 at Cantor Fitzgerald
May 7, 2019 6:42 AM EDTCantor Fitzgerald analyst Elemer Piros raised the price target on GW Pharma (NASDAQ: GWPH) to $229.00 (from $196.00) while maintaining a Overweight rating following Q1 results.
Piros commented, "The company reported the first full quarter of EPIDIOLEX revenues of $33.5 million. Additionally, GWPH reported positive... More
